Please login to the form below

Not currently logged in
Email:
Password:

Cardio3 BioSciences appoints Warren Sherman chief medical officer

He joins the biopharma firm from Columbia University Medical Center

edit-C3BS_Dr-Warren-ShermanBelgian biopharma firm Cardio3 BioSciences has named Warren Sherman as its chief medical officer.

Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.

He will assume the role at the cardiovascular disease-focused company from November 1.

He joins from Columbia University Medical Center, where he served in numerous roles including director of stem cell research and regenerative medicine and interventional cardiologist.

Sherman said: “I am thrilled to be joining Cardio3 BioSciences as chief medical officer at such an exciting time in its clinical development phase.

“The accomplishments of this young and dynamic company are remarkable, and it is an enormous opportunity for me to be part of the most promising project in the fields of cell therapy and other treatments for cardiovascular diseases.”

Sherman is also founder of the Cardiovascular Research Foundation's international conference on cell therapy for cardiovascular disease (IC3D), a meeting for healthcare experts dedicated to the evolving file of cell-based therapies for the repair and regeneration of cardiac and vascular disease.

Christian Homsy, CEO of Cardio3 BioSciences, added: “We are very pleased to be able to count on Warren Sherman's expertise in clinical application, as well as his renowned scientific outreach for the further development of Cardio3 BioSciences' future projects in regenerative therapies and cardiovascular diseases.”

3rd November 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics